Business
Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate
About this update from Artiva Biotherapeutics, Inc.
[{"type":"image","alt":"Artiva Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Artiva Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":163,"url":"https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qlnfoD..J1RiP0FeWYqi_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43","width":300,"height":163}},"lazy":false},{"type":"text","content":"SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA.","length":424,"tagName":"p"},{"type":"text","content":"Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference.","length":166,"tagName":"p"},{"type":"text","content":"Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.","length":230,"tagName":"p"},{"type":"text","content":"About Artiva Biotherapeutics","length":28,"tagName":"p"},{"type":"text","content":"Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic can...